Sanofi - Regeneron's Libtayo/Chemo Treatment Improves Overall Survival First-Line Lung CancerBenzinga • 08/05/21
Regeneron Beats Street Estimates Big In Q2 As COVID-19 Antibody Boosts Topline, Cuts FY21 R&D Spend OutlookBenzinga • 08/05/21
Regeneron shares jump 3.3% premarket after earnings blow past estimates; COVID antibody sales total $2.59 billionMarket Watch • 08/05/21
Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancerGlobeNewsWire • 08/05/21
Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung CancerPRNewsWire • 08/05/21
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Prevent SARS-CoV-2 InfectionPRNewsWire • 08/04/21
Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMNZacks Investment Research • 08/04/21
Regeneron Announces the 2021 Winners of the Regeneron Prize for Creative InnovationPRNewsWire • 08/03/21
FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure ProphylaxisBenzinga • 08/02/21
Regeneron - Sanofi's Dupixent Improves Itch, Hives In Inflammatory Skin Disease PatientsBenzinga • 07/29/21
Dupixent® (dupilumab) Significantly Improved Itch and Hives in Patients with Chronic Spontaneous Urticaria, a Step Forward in Demonstrating the Role of Type 2 Inflammation in These PatientsPRNewsWire • 07/29/21
Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for ObesityPRNewsWire • 07/27/21
Sanofi-Regeneron's COPD Drug Fails In Mid-Stage Trial, But Shows Potential Benefit In Subgroup of Former SmokersBenzinga • 07/22/21